Concord Drugs (BOM:538965) EV-to-EBITDA : 11.55 (As of May. 01, 2024)

Concord Drugs EV-to-EBITDA Chart

Concord Drugs Annual Data
	Trend	Mar14	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23
EV-to-EBITDA		Get a 7-Day Free Trial					7.04	6.23	5.48	7.33	9.22

Concord Drugs Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															6.64	9.22	4.95	8.41	12.73

Competitive Comparison of Concord Drugs's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Concord Drugs's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Concord Drugs's EV-to-EBITDA falls into.

Concord Drugs EV-to-EBITDA Calculation

Concord Drugs's EV-to-EBITDA for today is calculated as:

Concord Drugs's current Enterprise Value is ₹541.7 Mil.
Concord Drugs's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹46.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Drugs  (BOM:538965) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Concord Drugs's PE Ratio for today is calculated as:

Concord Drugs's share price for today is ₹37.47.
Concord Drugs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1.010.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Concord Drugs EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Concord Drugs's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Concord Drugs (BOM:538965) Business Description